Teva’s mAb shows benefit in celiac disease study

While Teva announced positive Phase II data, it has not yet confirmed Phase III plans for the celiac disease candidate. While Teva announced positive Phase II data, it has not yet confirmed Phase III plans. Teva has not yet revealed its Phase III plans for the candidate. Credit: Jonathan Weiss / Shutterstock.com Teva’s investigational anti-interleukin-15 monoclonal antibody (mAb) has met its primary endpoint in a Phase IIa trial in celiac disease. In the study, TEV ‘408 met its primary endpoint of villus height to crypt depth ratio (Vh:Cd) change, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage…

Source: Clinical Trials Arena